Bunge Free cash flow increased by 40.7% to -$877.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 47.4%, from -$595.00M to -$877.00M. Over 3 years (FY 2021 to FY 2024), Free cash flow shows an upward trend with a -45.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$823.25M | -$823.25M | -$823.25M | -$1.53B | -$1.53B | -$1.53B | -$1.53B | $758.00M | -$827.00M | $1.12B | $1.13B | $758.00M | -$1.77B | $973.00M | $564.00M | -$595.00M | -$1.48B | -$877.00M |
| QoQ Change | — | +0.0% | +0.0% | -85.4% | +0.0% | +0.0% | +0.0% | +149.7% | -209.1% | +235.9% | +0.6% | -33.0% | -333.6% | +154.9% | -42.0% | -205.5% | -148.4% | +40.7% |
| YoY Change | — | — | — | — | -85.4% | -85.4% | -85.4% | +149.7% | +45.8% | +173.7% | +174.1% | +0.0% | -114.1% | -13.4% | -50.1% | -178.5% | +16.5% | -47.4% |